Simon Chowdhury Selected Research

apalutamide

2/2022	Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
1/2022	Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
1/2022	Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
10/2021	Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
10/2021	Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
7/2021	Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
1/2021	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
1/2021	Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
1/2021	Apalutamide and Overall Survival in Prostate Cancer.
1/2020	Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Simon Chowdhury Research Topics

Disease

67	Prostatic Neoplasms (Prostate Cancer) 10/2022 - 01/2010
31	Neoplasms (Cancer) 01/2022 - 02/2003
21	Neoplasm Metastasis (Metastasis) 02/2022 - 12/2013
16	Disease Progression 10/2022 - 09/2011
15	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 08/2007
12	Fatigue 10/2022 - 07/2014
10	Urinary Bladder Neoplasms (Bladder Cancer) 01/2019 - 05/2015
7	Pain (Aches) 10/2021 - 05/2015
6	Kidney Neoplasms (Kidney Cancer) 10/2016 - 01/2011
5	Exanthema (Rash) 01/2022 - 04/2018
4	Hypertension (High Blood Pressure) 01/2022 - 07/2014
4	Breast Neoplasms (Breast Cancer) 12/2006 - 09/2005
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 04/2014
3	Nausea 01/2020 - 08/2014
2	Anemia 01/2022 - 01/2016
2	Back Pain (Backache) 01/2018 - 02/2016
2	Carcinoma (Carcinomatosis) 01/2018 - 01/2017
2	Obesity 12/2016 - 09/2014
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2014 - 04/2014
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2007 - 08/2005
1	Lymphadenopathy 03/2022
1	Pruritus (Itching) 01/2022
1	Septic Shock (Toxic Shock Syndrome) 01/2022
1	Adenocarcinoma 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Sudden Death 01/2022
1	Asthenia 01/2022
1	Microsatellite Instability 01/2021
1	Testicular Neoplasms (Testicular Cancer) 01/2020
1	Headache (Headaches) 01/2020
1	Heart Diseases (Heart Disease) 01/2020
1	Diabetes Mellitus 01/2020

Drug/Important Bio-Agent (IBA)

20	enzalutamideIBA 10/2022 - 03/2014
20	AndrogensIBA 10/2022 - 12/2011
14	Hormones (Hormone)IBA 10/2022 - 09/2005
14	apalutamideIBA 02/2022 - 04/2018
12	Docetaxel (Taxotere)FDA Link 10/2022 - 12/2013
10	Prostate-Specific Antigen (Semenogelase)IBA 02/2022 - 12/2016
10	Biomarkers (Surrogate Marker)IBA 07/2021 - 09/2011
9	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 07/2014
7	abirateroneIBA 10/2022 - 03/2014
7	Abiraterone AcetateIBA 10/2022 - 01/2017
6	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 12/2016
5	Prednisolone (Predate)FDA LinkGeneric 10/2022 - 01/2017
5	Immune Checkpoint InhibitorsIBA 03/2022 - 01/2018
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 06/2012
4	Prednisone (Sone)FDA LinkGeneric 10/2022 - 02/2014
4	rucaparibIBA 01/2022 - 01/2020
4	pazopanib FDA Link 10/2021 - 10/2016
4	PlatinumIBA 01/2020 - 08/2005
4	bicalutamide (Casodex)FDA LinkGeneric 09/2018 - 02/2016
4	Sunitinib (Sutent)FDA Link 10/2011 - 01/2011
3	antiarrhythmic peptide (AAP)IBA 10/2022 - 01/2021
3	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2021
3	Testosterone (Sustanon)FDA Link 01/2021 - 04/2013
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 11/2020
3	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 06/2014
2	Alanine (L-Alanine)FDA Link 01/2022 - 01/2022
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2006
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2022 - 01/2021
2	pembrolizumabIBA 10/2021 - 01/2021
2	B7-H1 AntigenIBA 01/2021 - 05/2015
2	Taxoids (Taxanes)IBA 01/2020 - 12/2018
2	Biological ProductsIBA 01/2020 - 09/2014
2	cabazitaxel FDA Link 12/2018 - 12/2015
2	RadiopharmaceuticalsIBA 01/2018 - 04/2015
2	LigandsIBA 10/2016 - 10/2015
2	Gonadotropin-Releasing Hormone (GnRH)FDA Link 04/2015 - 04/2013
2	Radium-223IBA 04/2015 - 02/2014
2	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 08/2014 - 12/2013
2	Estrogens (Estrogen)FDA Link 09/2006 - 12/2005
2	Aromatase InhibitorsIBA 12/2005 - 09/2005
2	Single-Chain AntibodiesIBA 01/2004 - 02/2003
1	atezolizumabIBA 03/2022
1	cabozantinibIBA 03/2022
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022
1	AntibodiesIBA 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022
1	Acetates (Acetic Acid Esters)FDA Link 01/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022
1	metabotropic glutamate receptor type 1IBA 01/2022
1	darolutamideIBA 01/2022
1	Phenobarbital (Luminal)FDA Link 07/2021
1	Circulating Tumor DNAIBA 01/2021
1	durvalumabIBA 01/2021
1	EnzymesIBA 01/2021
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2021
1	ParaffinIBA 11/2020
1	Formaldehyde (Formol)FDA Link 11/2020
1	thiamine triphosphorate (TTP)IBA 01/2020

Therapy/Procedure

56	Therapeutics 10/2022 - 08/2005
47	Castration 03/2022 - 01/2010
20	Drug Therapy (Chemotherapy) 01/2021 - 08/2005
7	Radiotherapy 01/2022 - 04/2013
7	Nephrectomy 01/2021 - 12/2008
4	Cystectomy 12/2018 - 08/2015
4	Immunotherapy 05/2016 - 08/2007
3	Duration of Therapy 01/2020 - 12/2006
2	Chemoradiotherapy 04/2018 - 10/2016